Neurocysticercosis: Clinical Case

Authors

  • Marco Antonio Rojas Gutiérrez Hospital Regional de la Orinoquía, Yopal, Colombia
  • Stefanía Buitrago Cárdenas Universidad Rafael Núñez, Cartagena Colombia
  • Ana Maria Ramos Páez Universidad Cooperativa de Colombia, Villavicencio, Colombia
  • Ledmar J. Vargas Rodríguez Universidad de Boyacá, Tunja, Colombia https://orcid.org/0000-0001-6001-5720

DOI:

https://doi.org/10.17081/innosa.90

Keywords:

Cysticercosis, Neurocysticercosis, Taenua solium, brain, central nervous system

Abstract

Neurocysticercosis (NCC) is a parasitic infection of the nervous system caused by Taenia Solium. Case report: A 42-year-old patient with headache. The tomography and the resonance can be used with nerocisticercosis, additionally in the ELISA test in CSF it was positive for T. Solium. Discussion: It is a low prevalence entity. It can be classified as parenchymal, subarachnoid, ventricular, spinal and / or mixed. The diagnosis has been oriented from the presence of risk factors, the clinical picture and the imaging findings. The treatment is necessary with albendazole.

Downloads

Download data is not yet available.

References

Jiménez OH, Nagore N. Endoscopic evidence of ventricular and cisternal inflammatory changes after intraoperative cysticercal rupture during endoscopic third-ventriculostomy removal. Br J Neurosurg. 2013; 27:137– 8. DOI: 10.3109/02688697.2012.703348

Clinton A, Coyle C, Rajshekhar V, Singh G, Allen W, Mohanty A, et al. Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2017; 66 (15): 49 – 75. DOI: 10.1093/cid/cix1084

Astrid Carolina Flórez Sánchez, Sandra Magnolia Pastrán, Nirley Stella Vargas, Mauricio Beltrán, Yamile Enriquez, Adriana Paola Peña, et al. Cisticercosis en Colombia. Estudio de seroprevalencia 2008 – 2010. Acta Neurol Colomb. 2013; 29 (2): 73 - 86. Disponible en: http://www.scielo.org.co/scielo.php?pid=S0120-87482013000200003&script=sci_abstract&tlng=es

Moyano LM, O’Neal SE, Ayvar V. Cysticercosis Working Group in Peru. High prevalence of asymptomatic neurocysticercosis in an endemic rural community in Peru. PLoS Negl Trop Dis 2016; 10: e0005130. DOI: 10.1371/journal.pntd.0005130

Garcia HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol. 2014; 13:1202–15. DOI: 10.1016/S1474-4422(14)70094-8

O’Neal SE, Flecker RH. Hospitalization frequency and charges for neurocysticercosis, United States, 2003–2012. Emerg Infect Dis 2015; 21:969–76. DOI: 10.3201/eid2106.141324

Del Brutto OH, Lama J. The importance of neurocysticercosis in stroke in rural areas of a developing Latin American country. Am J Trop Med Hyg 2013; 89:374–381. DOI: 10.4269/ajtmh.13-0196

Hernández RD, Durán BB, Lujambio PS. Magnetic resonance imaging in neurocysticercosis. Top Magn Reson Imaging 2014; 23 (3):191–8. DOI: 10.1097/RMR.0000000000000026

Carod JF, Randrianarison M, Razafimahefa J. Evaluation of the performance of 5 commercialized enzyme immunoassays for the detection of Taenia solium antibodies and for the diagnosis of neurocysticercosis. Diagn Microbiol Infect Dis 2012; 72:85–9. DOI: 10.1016/j.diagmicrobio.2011.09.014

Del Brutto, O. H., V. Rajshekhar, A. C. White, Jr., V. C. Tsang, T. E. Nash, O. M. Takayanagui, P. M. Schantz, C. A. Evans, A. Flisser, D. Correa, D. Botero, J. C. Allan, E. Sarti, A. E. Gonzalez, R. H. Gilman, and H. H. Garcia. 2001. Proposed diagnostic criteria for neurocysticercosis. Neurology 57:177-183. DOI: 10.1212/wnl.57.2.177

Del Brutto, O. H., N. H. Wadia, M. Dumas, M. Cruz, V. C. Tsang, and P. M. Schantz. 1996. Proposal ofdiagnostic criteria for human cysticercosis and neurocysticercosis. J. Neurol. Sci. 142:1-6. DOI: 10.1016/0022-510x(96)00130-x

Garcia HH, Evans CA, Nash TE, Takayanagui OM, White AC Jr, Botero D, Rajshekhar V, Tsang VC,Schantz PM, Allan JC, Flisser A, Correa D, Sarti E, Friedland JS, Martinez SM, Gonzalez AE, Gilman RH,Del Brutto OH. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002Oct;15(4):747-56. DOI: 10.1128/CMR.15.4.747-756.2002

Serpa JA, Graviss EA, Kass JS, White AC. Neurocysticercosis in Houston, Texas: an update. Medicine(Baltimore) 2011; 90:81–6. DOI: 10.1097/MD.0b013e318206d13e

Carrillo Mezo R, Lara García J, Arroyo M, Fleury A. Relevance of 3D magnetic resonance imaging sequencesin diagnosing basal subarachnoid neurocysticercosis. Acta Trop 2015; 152:60. DOI: 10.1016/j.actatropica.2015.08.017

Lerner A, Shiroishi MS, Zee CS, Law M, Go JL. Imaging of neurocysticercosis. Neuroimaging Clin N Am2012; 22:659–76. DOI: 10.1016/j.nic.2012.05.004

Del Brutto OH, Nash TE, White AC Jr, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci2017; 372:202–10. DOI: 10.1016/j.jns.2016.11.045

Garcia HH, Castillo Y, Gonzales I, et al. Low sensitivity and frequent cross-reactions in commercially availableantibody detection ELISA assays for Taenia solium cysticercosis. Trop Med Int Health 2018; 23:101 – 7. DOI: 10.1111/tmi.13010

Albenza (albendazole). Product information. Philadelphia, PA: SmithKline Beecham. Disponible en:https://www.accessdata.fda.gov/drugsatfda_docs/ label/2015/207844s000lbl.pdf

Garcia HH, Lescano AG, Gonzales I. Cysticercosis Working Group in Peru. Cysticidal efficacy of combinedtreatment with praziquantel and albendazole for parenchymal brain cysticercosis. Clin Infect Dis 2016; 62:1375–9. DOI: 10.1093/cid/ciw134

.Romo ML, Wyka K, Carpio A, et al. Ecuadorian Neurocysticercosis Group. The effect of albendazoletreatment on seizure outcomes in patients with symptomatic neurocysticercosis. Trans R Soc Trop Med Hyg2015; 109:738–46. DOI: 10.1093/trstmh/trv078

Carpio A, Kelvin EA, Bagiella E. Ecuadorian Neurocysticercosis Group. Effects of albendazole treatment onneurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008; 79:1050–5. DOI: 10.1136/jnnp.2008.144899

Solís AM, Tello Chumpitaz TJ, Quinte DH, Ramírez SE. Prevalencia y factores de riesgo asociados aneurocisticercosis en trabajadores del camal Conchucos, El Agustino, Perú. Acta Méd. Peru. 2007; 24 (3):167-171. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1728-59172007000300007

Saavedra Herbert, Gonzales Isidro, Alvarado Manuel A., Porras Miguel A., Vargas Victor, Cjuno Román A.et al. Diagnóstico y manejo de la neurocisticercosis en el Perú. Rev. Perú. med. exp. Salud pública [Internet]. 2010 Oct [citado 2020 Jul 19]; 27(4): 586-591. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342010000400015&lng=es

Additional Files

Published

2020-09-24

How to Cite

1.
Rojas Gutiérrez MA, Buitrago Cárdenas S, Ramos Páez AM, Vargas Rodríguez LJ. Neurocysticercosis: Clinical Case. Ciencia e Innovación en Salud [Internet]. 2020 Sep. 24 [cited 2026 Apr. 25];. Available from: https://revistas.unisimon.edu.co/index.php/innovacionsalud/article/view/3937

Issue

2020

Section

ORIGINALS

License

Copyright (c) 2020 Ledmar J. Vargas Rodríguez

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)